VRDN - Viridian Therapeutics, Inc.\DE

QQQ $ 473.16 $ -2.18 (-0.46 %)

DIA $ 417.33 $ 2.39 (0.58 %)

SPY $ 562.48 $ 1.01 (0.18 %)

TLT $ 101.29 $ 0.88 (0.88 %)

GLD $ 238.61 $ -0.07 (-0.03 %)

Previous Close

$ 22.06

Open

$ 22.17

Bid

$ 21.53 x 570

Ask

$ 21.57 x 100

Day's Range

$ 20.92 - $ 23.76

52 Week Range

$ 10.93 - $ 24.18

Volume

2,230,904

Average Volume

Market Cap

1.41B

Beta (5Y Monthly)

$ 0.21

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-08-2024	06-30-2024	10-Q
2	05-08-2024	03-31-2024	10-Q
3	02-27-2024	12-31-2023	10-K
4	11-13-2023	09-30-2023	10-Q
5	08-08-2023	06-30-2023	10-Q
6	05-10-2023	03-31-2023	10-Q
7	03-09-2023	12-31-2022	10-K
8	11-14-2022	09-30-2022	10-Q
9	08-15-2022	06-30-2022	10-Q
10	05-13-2022	03-31-2022	10-Q
11	03-11-2022	12-31-2021	10-K
12	11-05-2021	09-30-2021	10-Q
13	08-12-2021	06-30-2021	10-Q
14	05-07-2021	03-31-2021	10-Q
15	03-26-2021	12-31-2020	10-K
16	11-12-2020	09-30-2020	10-Q
17	08-05-2020	06-30-2020	10-Q
18	05-08-2020	03-31-2020	10-Q
19	03-13-2020	12-31-2019	10-K
20	11-08-2019	09-30-2019	10-Q
21	08-08-2019	06-30-2019	10-Q
22	05-09-2019	03-31-2019	10-Q
23	03-14-2019	12-31-2018	10-K
24	11-07-2018	09-30-2018	10-Q
25	08-08-2018	06-30-2018	10-Q
26	05-09-2018	03-31-2018	10-Q
27	03-15-2018	12-31-2017	10-K
28	11-09-2017	09-30-2017	10-Q
29	08-11-2017	06-30-2017	10-Q
30	05-11-2017	03-31-2017	10-Q
31	03-24-2017	12-31-2016	10-K
32	10-26-2016	09-30-2016	10-Q
33	08-15-2016	06-30-2016	10-Q
34	05-16-2016	03-31-2016	10-Q
35	03-21-2016	12-31-2015	10-K
36	11-13-2015	09-30-2015	10-Q
37	08-14-2015	06-30-2015	10-Q
38	05-15-2015	03-31-2015	10-Q
39	03-27-2015	12-31-2014	10-K
40	11-14-2014	09-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

RBC Capital Maintains Outperform on Viridi...
09/13/2024 13:54:39

RBC Capital analyst Gregory Renza maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price targe...

Goldman Sachs Maintains Buy on Viridian Th...
09/12/2024 15:45:44

Goldman Sachs analyst Richard Law maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from ...

Reported Earlier, Viridian Therapeutics Pr...
09/12/2024 06:53:21

Viridian is selling a total of 10,666,600 shares of common stock at a public offering price of $18.75 per share and 20,000 shar...

Needham Maintains Buy on Viridian Therapeu...
09/11/2024 11:06:33

Needham analyst Serge Belanger maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $30...

Viridian Therapeutics Announces $150M Prop...
09/10/2024 20:01:49

Critical Insights From Viridian Therapeuti...
09/10/2024 20:00:36

HC Wainwright & Co. Reiterates Buy on Viri...
09/10/2024 17:43:16

HC Wainwright & Co. analyst Douglas Tsao reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Buy and maintains $27 pri...

BTIG Maintains Buy on Viridian Therapeutic...
09/10/2024 15:47:29

BTIG analyst Julian Harrison maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $46 t...

calavo-growers-posts-better-than-expected-earnings-joins-tesla-oracle-mission-produce-and-other-big-stocks-moving-higher-on-tuesday

Calavo Growers Posts Better-Than-Expected ...
09/10/2024 14:07:31

viridian-therapeutics-discloses-exciting-data-from-experimental-thyroid-eye-disease-candidate-says-data-met-high-bars-for-efficacy-safety

Viridian Therapeutics Discloses 'Exciting'...
09/10/2024 13:14:50

Viridian Therapeutics announced promising topline data from the THRIVE phase 3 trial of VRDN-001 (veligrotug) for active thyroi...

Market-Moving News for September 10th
09/10/2024 11:52:43

ORCL: 9% | Oracle shares are trading higher following better-than-expected Q1 financial results. JMP Securities upgraded the st...

Viridian Therapeutics Says Veligrotug (VRD...
09/10/2024 11:07:49

Cash, cash equivalents, and short-term investments of $571.4 million as of June 30, 2024; provides cash runway into the second ...

why-oracle-shares-are-trading-higher-by-around-9-here-are-20-stocks-moving-premarket

Why Oracle Shares Are Trading Higher By Ar...
09/10/2024 10:41:15

Viridian Therapeutics To Host Webcast VRDN...
09/09/2024 20:03:39

- THRIVE global phase 3 clinical trial evaluated efficacy and safety of VRDN-001 in patients with active thyroid eye disease (T...

Needham Reiterates Buy on Viridian Therape...
08/30/2024 15:25:25

Needham analyst Serge Belanger reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Buy and maintains $30 price target.

RBC Capital Reiterates Outperform on Virid...
08/28/2024 12:53:24

RBC Capital analyst Gregory Renza reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and maintains $35 price t...

Decoding 6 Analyst Evaluations For Viridia...
08/15/2024 12:01:38

HC Wainwright & Co. Reiterates Buy on Viri...
08/15/2024 10:23:47

HC Wainwright & Co. analyst Douglas Tsao reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Buy and maintains $27 pri...

Oppenheimer Reiterates Outperform on Virid...
08/12/2024 13:48:18

Oppenheimer analyst Leland Gershell reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and lowers the price ta...

Viridian Therapeutics Q2 2024 Adj EPS $(1....
08/08/2024 12:29:48

Viridian Therapeutics (NASDAQ:VRDN) reported quarterly losses of $(1.02) per share which missed the analyst consensus estimate ...